Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

[1]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[2]  W. Small,et al.  A Phase 3 Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High-Risk, Early-Stage Endometrial Cancer: A Gynecology Oncology Group Study , 2017 .

[3]  H. Putter,et al.  Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  D. Matei,et al.  A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. , 2017 .

[5]  D. Gaffney,et al.  Brachytherapy Improves Survival in Stage III Endometrial Cancer With Cervical Involvement. , 2017, International journal of radiation oncology, biology, physics.

[6]  M. Stockler,et al.  Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial , 2016, British Journal of Cancer.

[7]  B. Yaremko,et al.  A Phase III Randomized Trial Comparing Patient-Reported Toxicity and Quality of Life (QOL) During Pelvic Intensity Modulated Radiation Therapy as Compared to Conventional Radiation Therapy. , 2016 .

[8]  H. Putter,et al.  Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. , 2016, The Lancet. Oncology.

[9]  P. Metcalfe,et al.  Results of the Australasian (Trans‐Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC‐3 trial , 2016, Journal of medical imaging and radiation oncology.

[10]  J. Ledermann,et al.  ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer , 2015, International Journal of Gynecologic Cancer.

[11]  T. Bosse,et al.  Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials. , 2015, European journal of cancer.

[12]  P. Pollock,et al.  Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative , 2015, Modern Pathology.

[13]  Gaetano Rocco,et al.  Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. C. Vos,et al.  Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. , 2014, Gynecologic oncology.

[15]  J. W. Kim,et al.  1A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Group trial , 2014 .

[16]  R. Barakat,et al.  Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer. , 2013, Gynecologic oncology.

[17]  H. Kitchener,et al.  Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: Taking Endometrial Cancer Trials Into the Translational Era , 2013, International Journal of Gynecologic Cancer.

[18]  B. Kahan,et al.  Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis , 2012, BMJ : British Medical Journal.

[19]  D. Miller,et al.  Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study , 2012 .

[20]  B. Kahan,et al.  Improper analysis of trials randomised using stratified blocks or minimisation , 2012, Statistics in medicine.

[21]  P. Zola,et al.  Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. , 2010, European journal of cancer.

[22]  L. Ramondetta,et al.  Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. , 2009, Gynecologic oncology.

[23]  V. Torri,et al.  Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. , 2009, Journal of the National Cancer Institute.

[24]  M. Parmar,et al.  Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study , 2009, The Lancet.

[25]  G. Fleming,et al.  The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. , 2007, Gynecologic oncology.

[26]  H Putter,et al.  Tutorial in biostatistics: competing risks and multi‐state models , 2007, Statistics in medicine.

[27]  J. Cooper,et al.  Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. , 2006, Gynecologic oncology.

[28]  P. Zola,et al.  Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial , 2006, British Journal of Cancer.

[29]  P. Boyle,et al.  Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. , 2004, Gynecologic oncology.

[30]  P. Koper,et al.  Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. Roland,et al.  Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy. , 2003, Gynecologic oncology.

[32]  A. Mundt,et al.  Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[33]  W. Curran,et al.  Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium. , 1990, International journal of radiation oncology, biology, physics.

[34]  N L Geller,et al.  The analysis of multiple endpoints in clinical trials. , 1987, Biometrics.

[35]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[36]  A. Secord,et al.  A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. , 2013, Gynecologic oncology.

[37]  Nobuyuki Susumu,et al.  Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. , 2008, Gynecologic oncology.